DPP_4抑制剂_从指南到临床.pptVIP

* * * Sitagliptin + Metformin: HbA1C Over 2 Years (Extension Study) [Note to Speaker: In the legend key, the numbers in parentheses for each treatment group represent the number of patients in each HbA1C subgroup of 8%, 8% and 9%, and 9%.] This 2-year extension study of a 54-week trial demonstrated that initial combination therapy with sitagliptin and metformin and monotherapy with either agent substantially lowered HbA1C in all subgroups of baseline HbA1C, with the greatest effects observed in patients with a baseline HbA1C of 9% or greater. The patients in the monotherapy groups were treated with sitagliptin 100 mg/day or metformin 500 or 1000 mg twice a day. The combination-therapy groups were treated twice daily with sitagliptin 50 mg and metformin 50 mg, or sitagliptin 50 mg and metformin 1000 mg. Over 104 weeks, substantial reductions from baseline were observed in all treatment groups. At each metformin dose studied, co-administration with sitagliptin provided a greater reduction in HbA1C than metformin monotherapy. For the sitagliptin 50 mg/metformin 1000 mg twice-daily group, the improvement in HbA1C was greater than with either agent alone. Greater reductions in HbA1C from baseline were observed in patients with higher baseline HbA1c levels. Reference Williams-Herman D, Johnson J, Teng R. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442-451. * * A.J.Scheen. Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors. Diabetologia. DOI 10.1007/s00125-012-2635-9 H. W. Rodbard P. S. Jellinger. A critique of the 2012 ADA/EASD position statement. Diabetologia. DOI 10.1007/s00125-012-2646-6 研究设计：一项荟萃分析，旨在评估二甲双胍单药治疗血糖控制不充分的2型糖尿病患者接受非胰岛素降糖药治疗的疗效、体重增加风险和低血糖事件发生率。研究者于MEDLINE搜索随机对照研究，并对27项研究进行分析。分析主要包括A1C、A1C达标率、体重和低血糖事件。 * 研究设计：一项系统性回顾和荟萃分析，旨在比较DPP-4抑制剂对亚洲2型糖尿病患者和非亚洲患者的降糖疗效。研究者于MEDLINE、EMBASE、LILACS、CENTRAL、C